[February 16, 2018] |
|
Global Amyloidosis Market Spotlight 2017-2027 - ResearchAndMarkets.com
The "Market
Spotlight: Amyloidosis" report has been added to ResearchAndMarkets.com's
offering.
This Market Spotlight report covers the amyloidosis market, comprising
key pipeline and marketed drugs, upcoming and regulatory events, patent
information, a 10-year disease prevalence forecast, and licensing and
acquisition deals.
Key Takeaways
-
The author estimates that in 2016, there were approximately 59,000
incident cases of amyloidosis worldwide, with the highest proportion
being the primary (amyloid light-chain; AL) amyloidosis type.
-
Among incident multiple myeloma cases, the author estimates there were
approximately 14,600 cases of AL amyloidosis worldwide in 2016.
-
Vyndaqel (tafamidis meglumine) is the only US Food and Drug
Administration (FDA)-approved drug for transthyretin (TTR)- related
hereditary amyloidosis (familial amyloid polyneuropathy).
-
There are more industry-sponsored drugs in active clinical development
for amyloidosis in Phase III than in any other phase. Therapies in
development for amyloidosis focus on targets such as TTR, AL, cluster
of differentiation (CD)38, proteasome, and serum amyloid P (SAP (News - Alert))
component. The majority of therapies in development for amyloidosis
are administered via the intravenous route, with the remainder being
oral and subcutaneous formulations.
-
High-impact upcoming events for drugs in te amyloidosis space include
topline Phase III trial results for patisiran. There were seven
licensing and asset acquisition activities involving amyloidosis drugs
during 2012-17. The largest deal during that time was the $1,135m
exclusive worldwide licensing and development agreement (in August
2012) between Janssen Biotech and Genmab, for the development and
commercialization of Genmab's daratumumab and a backup human CD38
antibody.
-
The clinical trials distribution across Phases I-IV indicates that the
majority of trials for amyloidosis have been in early and midphases of
development, with 80% of trials in Phase I-II and only 20% in Phase
III-IV.
-
The US has a substantial lead in the number of amyloidosis clinical
trials globally. The UK leads the major EU markets, while Japan has
the top spot in Asia.
-
Clinical trial activity in the amyloidosis space is dominated by
completed trials. GlaxoSmithKline has the highest number of completed
clinical trials for amyloidosis, with four.
-
Pfizer has carried out the most Phase III trials in amyloidosis (with
three), followed by Alnylam, which has sponsored one Phase III trial.
Key Topics Covered:
KEY TAKEAWAYS
DISEASE BACKGROUND
Amyloidosis subtypes
TREATMENT
Chemotherapy
Targeted therapy
Surgery
Bone marrow/stem cell transplantation
Palliative or supportive care
EPIDEMIOLOGY
Amyloidosis in multiple myeloma incidence methodology
MARKETED DRUGS
Approvals by country
PIPELINE DRUGS
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
GSK Passes On Taking Inotersen To FDA With Ionis
Fortress Subsidiary Licenses Amyloidosis Candidate From Columbia
PARENT PATENTS
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
APOLLO Success Clears Alnylam For Lift-Off
Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoint
Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings
Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or
Efficacy?
Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen
In Studies
BIBLIOGRAPHY
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/research/h5gm8z/global?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20180216005247/en/
[ Back To TMCnet.com's Homepage ]
|